These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36344724)

  • 1. Activities of (Poly)phenolic Antioxidants and Other Natural Autophagy Modulators in the Treatment of Sanfilippo Disease: Remarkable Efficacy of Resveratrol in Cellular and Animal Models.
    Rintz E; Podlacha M; Cyske Z; Pierzynowska K; Węgrzyn G; Gaffke L
    Neurotherapeutics; 2023 Jan; 20(1):254-271. PubMed ID: 36344724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
    Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
    Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
    Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
    J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C.
    Pshezhetsky AV
    Autophagy; 2016 Jun; 12(6):1059-60. PubMed ID: 25998837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive binding of extracellular accumulated heparan sulfate reduces lysosomal storage defects and triggers neuronal differentiation in a model of Mucopolysaccharidosis IIIB.
    De Pasquale V; Scerra G; Scarcella M; D'Agostino M; Pavone LM
    Biochim Biophys Acta Mol Cell Res; 2021 Oct; 1868(11):119113. PubMed ID: 34329663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has resveratrol a potential for mucopolysaccharidosis treatment?
    Rintz E; Pierzynowska K; Podlacha M; Węgrzyn G
    Eur J Pharmacol; 2020 Dec; 888():173534. PubMed ID: 32877657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H
    Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.
    Kloska A; Jakóbkiewicz-Banecka J; Narajczyk M; Banecka-Majkutewicz Z; Węgrzyn G
    Metab Brain Dis; 2011 Mar; 26(1):1-8. PubMed ID: 21305347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.
    Ellinwood NM; Wang P; Skeen T; Sharp NJ; Cesta M; Decker S; Edwards NJ; Bublot I; Thompson JN; Bush W; Hardam E; Haskins ME; Giger U
    J Inherit Metab Dis; 2003; 26(5):489-504. PubMed ID: 14518829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.
    Harm TA; Hostetter SJ; Nenninger AS; Valentine BN; Ellinwood NM; Smith JD
    Vet Pathol; 2021 Jan; 58(1):205-222. PubMed ID: 33205707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosaminoglycans and mucopolysaccharidosis type III.
    Jakobkiewicz-Banecka J; Gabig-Ciminska M; Kloska A; Malinowska M; Piotrowska E; Banecka-Majkutewicz Z; Banecki B; Wegrzyn A; Wegrzyn G
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1393-409. PubMed ID: 27100513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice.
    Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD
    Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sanfilippo syndrome type B: Analysis of patients diagnosed by the MPS Brazil Network.
    Montenegro YHA; de Souza CFM; Kubaski F; Trapp FB; Burin MG; Michelin-Tirelli K; Leistner-Segal S; Facchin ACB; Medeiros FS; Giugliani L; Ribeiro EM; Lourenço CM; Cardoso-Dos-Santos AC; Ribeiro MG; Kim CA; Castro MAA; Embiruçu EK; Steiner CE; Moreira MLC; Montano HQ; Baldo G; Giugliani R
    Am J Med Genet A; 2022 Mar; 188(3):760-767. PubMed ID: 34806811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice.
    Mohammed EE; Snella EM; Rutz-Mendicino MM; Echevarria FD; Awedikian R; Whitley EM; Ellinwood NM
    Mol Genet Metab; 2012 Sep; 107(1-2):129-35. PubMed ID: 22867887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sanfilippo syndrome: a mini-review.
    Valstar MJ; Ruijter GJ; van Diggelen OP; Poorthuis BJ; Wijburg FA
    J Inherit Metab Dis; 2008 Apr; 31(2):240-52. PubMed ID: 18392742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
    Yogalingam G; Luu AR; Prill H; Lo MJ; Yip B; Holtzinger J; Christianson T; Aoyagi-Scharber M; Lawrence R; Crawford BE; LeBowitz JH
    PLoS One; 2019; 14(1):e0207836. PubMed ID: 30657762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.